2seventy bio (TSVT) Projected to Post Earnings on Tuesday

2seventy bio (NASDAQ:TSVT) is projected to post its quarterly earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $12.84 million for the quarter.

2seventy bio Price Performance

Shares of TSVT opened at $2.63 on Tuesday. 2seventy bio has a one year low of $2.29 and a one year high of $6.00. The firm has a market capitalization of $135.68 million, a P/E ratio of -1.41 and a beta of 1.74. The business has a fifty day moving average of $2.68 and a 200 day moving average of $3.81.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of 2seventy bio in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, 2seventy bio presently has a consensus rating of “Moderate Buy” and an average target price of $7.20.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.